The oncology and rare disease-focused biopharmaceutical company, Mereo BioPharma group PLC (MREO)’s stock is soaring in today’s premarket, May 9, 2022. At the time of
Mereo BioPharma Group PLC (MREO) is leading oncology and rare diseases-related biopharmaceutical company. The main product candidate of the company is etigilimab (OMP-313M32) for the
Mereo BioPharma Group plc (MREO) stock plunged -7.78% to $3.32 in the pre-market trading after declaring collaboration and license agreement with Ultragenyx Pharmaceutical Inc. (RARE),
Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.